WallStSmart
XFOR

X4 Pharmaceuticals Inc

NASDAQ: XFOR · HEALTHCARE · BIOTECHNOLOGY

$4.07
-0.73% today

Updated 2026-04-30

Market cap
$374.59M
P/E ratio
P/S ratio
10.67x
EPS (TTM)
$-1.87
Dividend yield
52W range
$1 – $5
Volume
0.5M

X4 Pharmaceuticals Inc (XFOR) Financial statements

SEC filings — annual and quarterly data.

Income statement — annual

Item20152016201720182019202020212022202320242025
Revenue$0.00$0.00$3.50M$3.00M$3.00M$0.00$0.00$0.00$2.56M$35.11M
Revenue growth (YoY)-14.3%+0.0%-100.0%+1273.2%
Cost of revenue$400000.00$300000.00$195000.00$103000.00$672000.00$1.23M$1.89M$1.99M$2.00M$797000.00$6.26M
Gross profit$-400000.00$-300000.00$-195000.00$-103000.00$-672000.00$3.00M$-1.89M$-1.99M$-2.00M$1.76M$28.86M
Gross margin-2.9%-22.4%100.0%68.8%82.2%
R&D$12.71M$17.83M$28.13M$20.35M$30.16M$41.93M$48.76M$61.06M$72.02M$81.64M$72.72M
SG&A$2.12M$6.51M$8.01M$18.41M$17.64M$20.94M$24.70M$27.02M$32.14M$61.52M$43.52M
Operating income$-14.82M$-24.35M$-36.13M$-29.09M$-46.80M$-59.87M$-75.35M$-87.57M$-107.52M$-36.40M$-86.88M
Operating margin-831.0%-1560.1%-1995.8%-1423.6%-247.4%
EBITDA$-14.43M$-24.05M$-35.94M$-28.98M$-46.13M$-59.52M$-73.46M$-89.33M$-94.89M$-27.58M$-85.61M
EBITDA margin-828.1%-1537.7%-1984.1%-1078.5%-243.8%
EBIT$-14.82M$-24.35M$-36.13M$-29.09M$-46.80M$-59.87M$-75.35M$-89.85M$-95.31M$-28.37M$-86.88M
Interest expense$472000.00$2.52M$2.08M$720000.00$2.15M$2.69M$3.64M$3.99M$5.78M$8.77M$8.88M
Income tax
Effective tax rate0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Net income$-13.22M$-22.98M$-33.88M$-33.28M$-52.81M$-62.13M$-88.70M$-93.87M$-101.17M$-37.45M$-79.20M
Net income growth (YoY)-73.8%-47.5%+1.7%-58.7%-17.7%-42.8%-5.8%-7.8%+63.0%-111.5%
Profit margin-951.0%-1760.2%-2071.0%-1464.6%-225.6%